{"id":684496,"date":"2019-10-31T20:00:00","date_gmt":"2019-10-31T20:00:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=ebf980aaeb3c2d96ee6982f29db720d1"},"modified":"2019-10-31T20:00:00","modified_gmt":"2019-10-31T20:00:00","slug":"replimune-to-host-investor-event-at-the-34th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/replimune-to-host-investor-event-at-the-34th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","title":{"rendered":"Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)"},"content":{"rendered":"<p><![CDATA[WOBURN, Mass., Oct.  31, 2019  (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced it will host an investor event to review the full safety, clinical efficacy, and biomarker data from Part 1 of the Phase 1\/2 clinical trial of RP1 alone and in combination with Opdivo\u00ae. The event will include a presentation by Robert Coffin, Ph.D., President and CEO of Replimune who will be joined by the principle investigator, Mark Middleton, MD, PhD, Professor of Experimental Cancer at the University of Oxford, and other senior members of the Replimune management team. The presentation will focus on the data being presented at SITC as well as additional supporting data from the clinical trial.]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/684496"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=684496"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/684496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=684496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=684496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=684496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}